A New FDA Approval Furthers the Role of Genomics in Cancer Care

FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.

from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2AE0c4i